

Efficacy of ginger (*Zingiber officinale*) in ameliorating chemotherapy-induced nausea and vomiting and chemotherapy-related outcomes: a systematic literature review update and meta-analysis

Crichton, Megan; Marshall, Skye; Marx, Wolfgang; Isenring, Elisabeth

Published in:
Supportive Care in Cancer

DOI:
[10.1007/s00520-018-4193-2](https://doi.org/10.1007/s00520-018-4193-2)

Licence:
CC BY-NC-ND

[Link to output in Bond University research repository.](#)

Recommended citation(APA):



Crichton, M., Marshall, S., Marx, W., & Isenring, E. (2018). Efficacy of ginger (*Zingiber officinale*) in ameliorating chemotherapy-induced nausea and vomiting and chemotherapy-related outcomes: a systematic literature review update and meta-analysis. *Supportive Care in Cancer*, 26(S2), S168. [eP242]. <https://doi.org/10.1007/s00520-018-4193-2>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.

Ginger for Chemotherapy-induced nausea and vomiting?



Authors declare no COI. Correspondence: spice@bond.edu.au. Twitter: @DrSkyeMarshall. <https://orcid.org/0000-0001-8953-5068>

Introduction

Gingerol and shogaol compounds in ginger likely interact with multiple components of the CINV pathway.

Previous systematic reviews (Marx et. al. 2013 and Lee & Oh 2013) found no consistent effect of ginger as an adjuvant therapy for CINV.

Research aim: To update previous systematic reviews which evaluate the efficacy of ginger supplementation in the prevention and management of CINV

Methods & Included Studies

Searched 5 databases → Included adults receiving CTx → Ginger versus placebo/control (including anti-emetics) → Searched 204 records → Included 18 studies (13 new ones) → n=1,652 total participants, 64% female, n=9/18 studies in breast cancer → Low risk of bias in most studies (Cochrane) → Meta-analysis via RevMan → Confidence in body of evidence assessed by GRADE.

Results

NAUSEA INCIDENCE




Figure 1: >1g/day for any duration significantly reduced odds of overall nausea incidence by 42%. GRADE level: very low

VOMITING INCIDENCE




Figure 3: ≤1g/day for any duration significantly reduced odds of overall vomiting incidence by 30%. GRADE level: low




Figure 2: Any dose for >3-days duration significantly reduced odds of overall nausea incidence by 27%. GRADE level: very low




Figure 4: Any dose for >3-days duration significantly reduced odds of overall vomiting by 40%. GRADE level: low

Takeaway messages

- ✓ No serious safety concerns identified beyond increased risk of reflux
- ✓ Consistent finding that >3 days of supplementation can improve nausea & vomiting incidence
- ✓ Evidence regarding dosing strength inconsistent likely to due to heterogeneity in active compounds
- ✓ Larger well-controlled studies should improve confidence in estimated effect sizes
- ✓ SPICE Trial currently underway in Qld Australia (n=300 Double Blind Placebo-RCT)